In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vanguard Medica develops Roche's endothelin antagonist

Executive Summary

Vanguard Medica will develop Ro 61-1790, Roche's endothelin antagonist compound for acute renal failure (ARF) prevention and sub-arachnoid hemorrhage (SAH). Roche completed preclinical and Phase I trials on the compound, renamed VML 588 by Vanguard.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies